Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GPRC5D

GPRC5D

Brief Information

Name:G-protein coupled receptor family C group 5member D
Target Synonym:G Protein-Coupled Receptor Class C Group 5 Member D,G-Protein Coupled Receptor Family C Group 5 Member D,G Protein-Coupled Receptor, Class C, Group 5, Member D,G Protein-Coupled Receptor, Family C, Group 5, Member D,GPRC5D,Orphan G-Protein Coupled Receptor
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
GPRC5D VHH - 01 PCC Hematological Malignancy Multiple myeloma

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GPD-H52D6 Human Human GPRC5D Full Length Protein, Flag,His Tag (Nanodisc)
GPD-H52D6-structure
GPD-H82D7 Human Biotinylated Human GPRC5D Full Length Protein, Flag,His,Avitag™ (Nanodisc)
GPD-H82D7-structure
GPD-H52D5 Human Human GPRC5D Full Length Protein, Flag,His Tag (Detergent)
GPD-H52D5-structure
GPD-H82D5 Human Biotinylated Human GPRC5D Full Length Protein, Flag,His,Avitag™ (Detergent)
GPD-H82D5-structure
GPD-M52D3 Mouse Mouse GPRC5D Protein, Flag,His Tag (Detergent)
GPD-M52D3-structure
GPD-M52D3-sds
GPD-M52P3 Mouse Mouse GPRC5D Full Length Protein (VLP)
GPD-HF2G5 Human Fluorescent Human GPRC5D Full Length Protein (VLP)
GPD-H52P7 Human Human GPRC5D Full Length Protein (VLP)
CCHO-STP078 Human CHO/Human GPRC5D Stable Cell Line
GPD-HF2D7 Human FITC-Labeled Human GPRC5D Protein, Flag,His Tag (Nanodisc)
GPD-HF2D7-structure
GPD-HF2D7-sds
GPD-C52D3 Cynomolgus Cynomolgus GPRC5D Protein, Flag,His Tag (Detergent) (SPR verified)
GPD-C52D3-structure
GPD-C52D3-sds
CHEK-STP042 Human HEK293/Human GPRC5D Stable Cell Line
GPD-C82D4 Cynomolgus Cynomolgus GPRC5D Protein, Flag,His Tag (Nanodisc)
GPD-C82D4-structure
GPD-C82D4-sds
ACRO Quality

Part of Bioactivity data

CCHO-STP078-Cell-based assay
GPRC5D FACS

FACS Analysis of CHO/Human GPRC5D Stable Cell Line.

FACS assay shows that Anti-GPRC5D antibody can bind to CHO/Human GPRC5D Stable Cell Line (Fig. B), and non-transfected CHO cells were used as a negative control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

Protocol
GPD-H52D5-SPR
GPRC5D SPR

Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) with an affinity constant of 57.7 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

Protocol
GPD-HF2D7-SPR
GPRC5D SPR

Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind FITC-Labeled Human GPRC5D Protein, Flag,His Tag (Cat. No. GPD-HF2D7) with an affinity constant of 9.29 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

Synonym Name

GPRC5D

Background

G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Talquetamab JNJ-7564; JNJ-64407564 Approved Johnson & Johnson Innovative Medicine, Genmab A/S TALVEY United States Multiple Myeloma Janssen Biotech Inc 2023-08-09 Hematologic Neoplasms; Multiple Myeloma Details
Talquetamab JNJ-7564; JNJ-64407564 Approved Johnson & Johnson Innovative Medicine, Genmab A/S TALVEY United States Multiple Myeloma Janssen Biotech Inc 2023-08-09 Hematologic Neoplasms; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LM-305 LM-305 Phase 2 Clinical LaNova Medicines Ltd Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
IBI-3003 IBI3003; IBI-3003 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Multiple Myeloma Details
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) Phase 2 Clinical Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital Multiple Myeloma Details
MBS-314 MBS-314 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Multiple Myeloma Details
CT-071 CT071; CT-071 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy（920th Hospital） Phase 2 Clinical The 920th Hospital Of Joint Logistics Support Force Of PLA Multiple Myeloma Details
Ori-CAR-017 Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T Phase 2 Clinical OriCell Therapeutics Co Ltd Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders Details
LBL-034 LBL-034 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms; Multiple Myeloma Details
CC-95266 CC-95266; BMS986393; BMS-986393 Phase 2 Clinical Juno Therapeutics Inc Multiple Myeloma Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) BMS-986453 Phase 1 Clinical Juno Therapeutics Inc Multiple Myeloma Details
SIM-0500 SIM-0500; SIM0500 Phase 1 Clinical Hainan Xiansheng Re Ming Pharmaceutical Co Ltd Bone Marrow Neoplasms; Multiple Myeloma Details
OriC-321 OriC-321; Ori-C-321 Phase 1 Clinical Zhejiang University, OriCell Therapeutics Co Ltd Multiple Myeloma Details
CAR-GPRC5D CAR-GPRC5D Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Forimtamig RG-6234 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
MCARH-109 Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc Multiple Myeloma Details
RO-7425781 RO-7425781 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) The Second People Hospital Of Guangdong Province Details
Anti-GPRC5D CAR-T Cells Therapy（Institute of Hematology & Blood Diseases Hospital） Institute Of Hematology & Blood Diseases Hospital Details
LM-305 LM-305 Phase 2 Clinical LaNova Medicines Ltd Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
IBI-3003 IBI3003; IBI-3003 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Multiple Myeloma Details
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) Phase 2 Clinical Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital Multiple Myeloma Details
MBS-314 MBS-314 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Multiple Myeloma Details
CT-071 CT071; CT-071 Phase 2 Clinical CARsgen Therapeutics Holdings Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Anti-GPRC5D CAR-T Cells Therapy（920th Hospital） Phase 2 Clinical The 920th Hospital Of Joint Logistics Support Force Of PLA Multiple Myeloma Details
Ori-CAR-017 Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T Phase 2 Clinical OriCell Therapeutics Co Ltd Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders Details
LBL-034 LBL-034 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms; Multiple Myeloma Details
CC-95266 CC-95266; BMS986393; BMS-986393 Phase 2 Clinical Juno Therapeutics Inc Multiple Myeloma Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) BMS-986453 Phase 1 Clinical Juno Therapeutics Inc Multiple Myeloma Details
SIM-0500 SIM-0500; SIM0500 Phase 1 Clinical Hainan Xiansheng Re Ming Pharmaceutical Co Ltd Bone Marrow Neoplasms; Multiple Myeloma Details
OriC-321 OriC-321; Ori-C-321 Phase 1 Clinical Zhejiang University, OriCell Therapeutics Co Ltd Multiple Myeloma Details
CAR-GPRC5D CAR-GPRC5D Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Plasma Cell; Multiple Myeloma Details
Forimtamig RG-6234 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
MCARH-109 Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc Multiple Myeloma Details
RO-7425781 RO-7425781 Phase 1 Clinical F. Hoffmann-La Roche Ltd Multiple Myeloma Details
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) The Second People Hospital Of Guangdong Province Details
Anti-GPRC5D CAR-T Cells Therapy（Institute of Hematology & Blood Diseases Hospital） Institute Of Hematology & Blood Diseases Hospital Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap